Article
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.
Leukemia - 1 Jun 2006
Villuendas R, Steegmann J L, Pollán M, Tracey L, Granda A, Fernández-Ruiz E, Casado L F, Martínez J, Martínez P, Lombardía L, Villalón L, Odriozola J, Piris M A
Abstract excerpt
The use of the tyrosine kinase inhibitor imatinib, which blocks the enzymatic action of the BCR-ABL fusion protein, has represented a critical advance in chronic myeloid leukemia (CML) treatment. However, a subset of patients initially fails to respond to this treatment. Use of complementary DNA (cDNA) microarray expression profiling allows the identification of genes whose expression is associated with imatinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.